Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01604395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

Study acronym: LGS
StatusRecruiting
PhaseNot specified
SponsorLG Chem
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: LG Life Sciences to LG Chemv5 Show 4 more changesShow less
    • Enrollment target: 2000 to 6000
    • Primary completion date: Jan 2020 to Dec 31, 2032
    • Study completion date: Jan 2022 to Dec 31, 2032
    • Study title expanded, about 2 words
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Jan 2020
    • Study completion date: Jan 2022
    v3
  4. Secondary endpoints revised (3)
    • Study title shortened, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
LG Chem
13 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Chronic Kidney Disease
1,417 trials monitored
See 68 trials at risk
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
Trial Details
NCT Number NCT01604395
Lead Sponsor LG Chem
Conditions
(from sponsor)		 Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age, Idiopathic Short Stature
Related terms Dwarfism, Pituitary, Kidney Failure, Chronic, Turner Syndrome
Enrollment 6,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov